NOTICE REGARDING NIDA CENTER GRANT CONSOLIDATED PROGRAM AND REVIEW GUIDELINES

RELEASE DATE:  August 20, 2003 
       
NOTICE:  NOT-DA-03-007

National Institute on Drug Abuse (NIDA)
 (http://www.nida.nih.gov)

PURPOSE

The purpose of this notice is to inform the research community that the 
National Institute on Drug Abuse (NIDA) has revised and clarified the 
consolidated program and review guidelines for its centers program.  This 
notice of Research Center Grant Consolidated Program and Review Guidelines 
will replace any previous guidelines.  

NIDA provides support for research center grants to foster a synergistic 
approach to drug abuse and addiction research and to enable studies that 
would not occur without the climate, facilities and research resources that a 
research center can uniquely provide.  NIDA centers must have two sets of 
essential and defining qualities.  The first of these is the highest caliber 
of scientific work.  The second set relates to the particular characteristics 
of research centers.  This set of center-specific characteristics emerges 
from the confluence of thematic integration, synergy, innovation, and 
multidisciplinary involvement.  A NIDA center is expected to enable a level 
of achievement that exceeds that expected on the basis of "the sum of its 
parts."  Center support should be essential to the achievement of work that 
is proposed.  The guidelines provide further details on the purpose of NIDA's 
centers program, characteristics of NIDA centers, eligibility criteria, 
application procedures, review criteria and procedures, and contacts for 
further information.

Applications will be accepted on an ongoing basis.  The receipt dates for all 
unsolicited center applications, whether new, competing renewal, or revised, 
are October 1, February 1 and June 1.  An applicant requesting $500,000 or 
more in direct costs for any year of a center is required to obtain agreement 
from the Institute program staff that the Institute is willing to accept the 
application for review and possible funding.  The name of the program contact 
should be indicated in a cover letter submitted with the application.  
Applications that do not identify a program contact will be returned to the 
applicant without review.

These revised guidelines are effective with applications submitted for the 
February 1, 2004, receipt date.  With the issuance of these guidelines, NIDA 
will no longer accept applications in response to the previous NIDA Research 
Center Program Guidelines, announced in the NIH Guide for Grants and 
Contracts on October 8, 1998 at 
https://grants.nih.gov/grants/guide/notice-files/not98-137.html.
  
The Research Center Grant Consolidated Program and Review Guidelines are 
available on NIDA's home page at http://www.nida.nih.gov under 
Funding/Opportunities and may be obtained from the address listed under 
INQUIRIES.  

INQUIRIES 

o Direct any questions about this notice to:

Rita Liu, Ph.D.
Office of Extramural Affairs
National Institute on Drug Abuse/NIH/DHHS
6001 Executive Boulevard, Room 3158, MSC 9547
Bethesda, MD  20892-9547
Telephone: (301) 443-2755
Email:  rliu@nida.nih.gov

Starting October 18, 2003, mail for the Office of Extramural Affairs, NIDA 
should be sent to:

Office of Extramural Affairs
National Institute on Drug Abuse/NIH/DHHS
6101 Executive Boulevard, Suite #200, MSC 8401
Bethesda, MD  20892-8401
Rockville, MD 20852 (express/courier service)
Telephone: (301) 443-2755

Applications submitted under these guidelines must be sent to the Center for 
Scientific Review at the address listed in the application form PHS-398.

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.